Could a switch to analogue insulin reduce dangerous low blood sugar in kids with diabetes?

NCT ID NCT05614089

Completed Disease control Sponsor: Jing Luo Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed Phase 4 trial enrolled 400 youth aged 7-25 with type 1 diabetes in low-resource settings. It compared insulin glargine (a long-acting analogue) to standard human insulin (NPH or premixed) to see if glargine reduces serious hypoglycemia or improves time in blood sugar range over 6 months. Participants used continuous glucose monitors to track outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: insulin glargine (a long-acting insulin analogue)
What this could lead to: If it works, this could show that insulin glargine is safer and more effective than cheaper human insulin for managing type 1 diabetes in low-resource settings.
What could go wrong: This is a completed Phase 4 trial, but results may not apply broadly due to the specific low-resource setting and strict eligibility criteria. The benefits of glargine over human insulin may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 1 TYPE 1 DIABETES

Contacts and locations

Locations

BIRDEM Hospital

Dhaka, Bangladesh
Bugando Medical Center

Mwanza, Tanzania
Sekou-Toure Hospital

Mwanza, Tanzania

More trials for these conditions

Other studies related to the condition(s) this trial covers.